Elevance Health (ELV) reported Q4 adjusted earnings Thursday of $3.84 per diluted share, down from $5.62 a year earlier.
Analysts surveyed by FactSet expected $3.81.
Total revenue for the quarter ended Dec. 31 was $45.44 billion, compared with $42.65 billion a year earlier.
Analysts surveyed by FactSet expected $44.92 billion.
For 2025, the company said it expects adjusted diluted EPS in the range of $34.15 to $34.85. A single analyst polled by FactSet expects $34.52.
Shares were up more than 4% in premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。